Results 151 to 160 of about 70,211 (203)

MCL restrained ROS/AKT/ASAH1 pathway to therapy tamoxifen resistance breast cancer by stabilizing NRF2. [PDF]

Cell Prolif
Han X, Zhang Y, Li Y, Lin Z, Fu Z, Wang C, Zhang S, Shao D, Li C.   +8 more
europepmc   +1 more source

Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. [PDF]

Cell Death Dis
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O.   +21 more
europepmc   +1 more source

Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance. [PDF]

Breast Cancer Res
Song T, Zhang H, Zhao Q, Hu Z, Wang Z, Song Y, Zhang Z.   +6 more
europepmc   +1 more source

Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer. [PDF]

Sci Rep
Fu H, Han X, Guo W, Zhao X, Yu C, Zhao W, Feng S, Wang J, Zhang Z, Lei K, Li M, Wang T.   +11 more
europepmc   +1 more source

Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93. [PDF]

Life (Basel)
Tsoi H, Shi L, Leung MH, Man EPS, So ZQ, Chan WL, Khoo US.   +6 more
europepmc   +1 more source

[Corrigendum] Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. [PDF]

Int J Oncol
Li Z, Yu D, Li H, Lv Y, Li S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mechanisms of tamoxifen resistance

Breast Cancer Research and Treatment, 1994
Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance.
C K, Osborne, S A, Fuqua
openaire   +2 more sources

Tamoxifen resistance in breast cancer

Critical Reviews in Oncology/Hematology, 1993
Tamoxifen (TAM) resistance is the underlying cause of treatment failure in many breast cancer patients receiving TAM. The mechanism(s) involved in TAM resistance are poorly understood. A variety of mechanisms have been proposed but only limited evidence exists to substantiate them.
V J, Wiebe, C K, Osborne, S A, Fuqua, M W, DeGregorio   +3 more
openaire   +2 more sources

Tamoxifen Resistance in Breast Cancer

Drugs, 2001
Tamoxifen has been used for the systemic treatment of patients with breast cancer for nearly three decades. Treatment success is primarily dependent on the presence of the estrogen receptor (ER) in the breast carcinoma. While about half of patients with advanced ER-positive disease immediately fail to respond to tamoxifen, in the responding patients ...
Dorssers, L.C.J., Flier, S. van der, Brinkmann, A.O., Agthoven, T. van, Veldscholte, J., Berns, E.M.J.J., Klijn, J.G.M., Beex, L.V.A.M., Foekens, J.A.   +8 more
openaire   +4 more sources

Tamoxifen resistance: From bench to bedside

European Journal of Pharmacology, 2013
Although tamoxifen is a classical example of a targeted drug, a substantial proportion of estrogen receptor alpha positive breast cancer patients does not benefit from the drug. Over the last few decades, many potential biomarkers have been discovered in cell biological studies that may aid in the prediction of tamoxifen sensitivity and guide in ...
Marjolein, Droog, Karin, Beelen, Sabine, Linn, Wilbert, Zwart   +3 more
openaire   +2 more sources